Transient Ischemic Attack
|
0.300 |
Biomarker
|
disease |
CTD_human |
Manganese Superoxide Dismutase Affects Cytochrome c Release and Caspase-9 Activation After Transient Focal Cerebral Ischemia in Mice.
|
11333366 |
2001 |
Posterior Circulation Transient Ischemic Attack
|
0.300 |
Biomarker
|
disease |
CTD_human |
Manganese Superoxide Dismutase Affects Cytochrome c Release and Caspase-9 Activation After Transient Focal Cerebral Ischemia in Mice.
|
11333366 |
2001 |
Carotid Circulation Transient Ischemic Attack
|
0.300 |
Biomarker
|
disease |
CTD_human |
Manganese Superoxide Dismutase Affects Cytochrome c Release and Caspase-9 Activation After Transient Focal Cerebral Ischemia in Mice.
|
11333366 |
2001 |
Transient Ischemic Attack, Vertebrobasilar Circulation
|
0.300 |
Biomarker
|
disease |
CTD_human |
Manganese Superoxide Dismutase Affects Cytochrome c Release and Caspase-9 Activation After Transient Focal Cerebral Ischemia in Mice.
|
11333366 |
2001 |
Crescendo Transient Ischemic Attacks
|
0.300 |
Biomarker
|
disease |
CTD_human |
Manganese Superoxide Dismutase Affects Cytochrome c Release and Caspase-9 Activation After Transient Focal Cerebral Ischemia in Mice.
|
11333366 |
2001 |
Brain Stem Ischemia, Transient
|
0.300 |
Biomarker
|
disease |
CTD_human |
Manganese Superoxide Dismutase Affects Cytochrome c Release and Caspase-9 Activation After Transient Focal Cerebral Ischemia in Mice.
|
11333366 |
2001 |
Transient Cerebral Ischemia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Manganese Superoxide Dismutase Affects Cytochrome c Release and Caspase-9 Activation After Transient Focal Cerebral Ischemia in Mice.
|
11333366 |
2001 |
Transient Ischemic Attack, Anterior Circulation
|
0.300 |
Biomarker
|
disease |
CTD_human |
Manganese Superoxide Dismutase Affects Cytochrome c Release and Caspase-9 Activation After Transient Focal Cerebral Ischemia in Mice.
|
11333366 |
2001 |
Fatty Liver
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mitochondrial adaptations to obesity-related oxidant stress.
|
10860543 |
2000 |
Steatohepatitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mitochondrial adaptations to obesity-related oxidant stress.
|
10860543 |
2000 |
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide association study of the rate of cognitive decline in Alzheimer's disease.
|
23535033 |
2014 |
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association study of the rate of cognitive decline in Alzheimer's disease.
|
23535033 |
2014 |
Chondrosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the effect of long-term exposure to 5% low oxygen atmosphere on human chondrosarcoma HCS-2/8 cells.
|
28865129 |
2018 |
Chondrosarcoma
|
0.050 |
GeneticVariation
|
disease |
BEFREE |
Meclozine also ameliorated abnormally suppressed proliferation of human chondrosarcoma (HCS-2/8) cells that were infected with lentivirus expressing constitutively active mutants of FGFR3-K650E causing thanatophoric dysplasia, FGFR3-K650M causing SADDAN, and FGFR3-G380R causing ACH.
|
24324705 |
2013 |
Chondrosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
New clonal-cell lines HCS-TG C3 and E2 derived from human chondrosarcoma are morphologically chondrocytic in serial monolayer cultures and express chondrocytic phenotypes.
|
15118855 |
2004 |
Chondrosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Cell density-dependent proliferative effects of transforming growth factor (TGF)-beta 1, beta 2, and beta 3 in human chondrosarcoma cells HCS-2/8 are associated with changes in the expression of TGF-beta receptor type I.
|
11458815 |
2001 |
Chondrosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
HCS-2/8 is a stable human chondrosarcoma cell line with many chondrocytic characteristics and has the capacity to form chondrosarcomas in nude mice.
|
8200849 |
1994 |
Scleroderma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Patients enrolled in the Scleroderma Lung Study II (cyclophosphamide [CYC] versus mycophenolate mofetil [MMF]) were included.
|
31233287 |
2019 |
Scleroderma
|
0.030 |
Biomarker
|
disease |
BEFREE |
A retrospective cohort of SSc subjects with ILD, disease duration below seven years and no exposure to CYC or MMF prior to the baseline visit was constructed from the Canadian Scleroderma Research Group registry.
|
31535689 |
2019 |
Systemic Scleroderma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Patients enrolled in the Scleroderma Lung Study II (cyclophosphamide [CYC] versus mycophenolate mofetil [MMF]) were included.
|
31233287 |
2019 |
Systemic Scleroderma
|
0.030 |
Biomarker
|
disease |
BEFREE |
A retrospective cohort of SSc subjects with ILD, disease duration below seven years and no exposure to CYC or MMF prior to the baseline visit was constructed from the Canadian Scleroderma Research Group registry.
|
31535689 |
2019 |
Lung Diseases, Interstitial
|
0.030 |
Biomarker
|
group |
BEFREE |
In both treatment arms (n = 71 for CYC, n = 62 for MMF), a higher baseline KL-6 level predicted progression of ILD based on the course of FVC (P = 0.024 for CYC; P = 0.005 for MMF) and DLco (P < 0.001 for CYC; P = 0.004 for MMF) over 1 year.
|
31233287 |
2019 |
Lung Diseases, Interstitial
|
0.030 |
Biomarker
|
group |
BEFREE |
Our aim was to determine whether use of CYC or MMF was associated with an improved ILD course in patients with normal or mildly impaired lung function.
|
31535689 |
2019 |
Scleroderma
|
0.030 |
Biomarker
|
disease |
BEFREE |
RTX is a safe and effective alternative to CYC in the primary therapy of skin and lung manifestations of scleroderma.
|
30053212 |
2018 |
Systemic Scleroderma
|
0.030 |
Biomarker
|
disease |
BEFREE |
RTX is a safe and effective alternative to CYC in the primary therapy of skin and lung manifestations of scleroderma.
|
30053212 |
2018 |